SALT LAKE CITY, March 24, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that Tesaro, Inc. will use Myriad's novel HRD (homologous recombination deficiency) test to identify tumor types that may respond to its investigational poly-ADP ribose polymerase (PARP) inhibitor, niraparib, currently in Phase 3 clinical development. Specific terms of the deal were not disclosed.
"The biology of cancer is complex and increasingly the goal of oncology is to use a companion diagnostic to pair a tumor type with the targeted activity of a specific medicine. Prior studies have shown that only a subset of patients will respond to PARP inhibitors. HRD is the most comprehensive test to identify those patients who might respond to treatment," said Jerry Lanchbury, Ph.D., chief scientific officer at Myriad. "The HRD test is engineered to look for evidence of genomic disrepair, which appears as a DNA scar. We believe using the HRD test may capture an enhanced number of responders to treatment with the exciting new class of PARP inhibitors."
The research agreement with Tesaro is Myriad's fifth collaboration with a major pharmaceutical company to evaluate HRD. Myriad estimates the global market for an HRD test could exceed $3 billion as oncologists move toward personalized medicine and targeted therapies."As an innovation-focused company, we are leading the way in developing breakthrough companion diagnostics that have the potential to create significant value for patients and physicians," said Lanchbury. "We also strive to be the research partner of choice. Myriad has a proven track record of providing our pharmaceutical partners with what they need to move their products forward and achieve success." About HRD ( Homologous Recombination Deficiency) Myriad's proprietary HRD test detects when a tumor has lost the ability to repair double-stranded DNA breaks resulting in increased susceptibility to DNA-damaging drugs. High HRD scores are prevalent in all breast cancer subtypes and most other major cancers. In previously published data, Myriad showed that the HRD test predicted drug response to platinum therapy in triple-negative breast cancer patients. It is estimated that 490,000 people in the United States who are diagnosed with cancers annually are candidates for treatment with DNA-damaging agents.